Abeona Therapeutics Inc.

NasdaqCM:ABEO Voorraadrapport

Marktkapitalisatie: US$261.6m

Abeona Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Abeona Therapeutics de winst en omzet met respectievelijk 53.4% en 62.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 56.3% per jaar.

Belangrijke informatie

53.4%

Groei van de winst

56.3%

Groei van de winst per aandeel

Biotechs winstgroei27.3%
Inkomstengroei62.7%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt31 Oct 2024

Recente toekomstige groei-updates

Recent updates

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Sep 23
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

May 01
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Jan 04
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16
Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31
Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28
Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21
Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19
How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15
What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Winst- en omzetgroeiprognoses

NasdaqCM:ABEO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202671-40-31-596
12/31/202514-71-52-666
12/31/20240-62-60-646
6/30/2024N/A-53-44-42N/A
3/31/20244-77-41-40N/A
12/31/20234-54-37-37N/A
9/30/20234-45-42-42N/A
6/30/20234-39-43-43N/A
3/31/20231-31-42-42N/A
12/31/20221-43-44-43N/A
9/30/20224-83-63-60N/A
6/30/20224-84-67-63N/A
3/31/20223-91-70-66N/A
12/31/20213-85-70-66N/A
9/30/20213-54-38-37N/A
6/30/202110-54-38-37N/A
3/31/202110-52-37-35N/A
12/31/202010-84-36-35N/A
9/30/20207-85-49-48N/A
6/30/2020N/A-95-57-55N/A
3/31/2020N/A-106-67-61N/A
12/31/2019N/A-76-69-63N/A
9/30/20190-77-83-66N/A
6/30/20192-76-74-56N/A
3/31/20192-65-67-50N/A
12/31/20183-57-59-39N/A
9/30/20183-48-36-27N/A
6/30/20181-37-33-25N/A
3/31/20181-33N/A-21N/A
12/31/20171-27N/A-23N/A
9/30/20171-26N/A-21N/A
6/30/20171-23N/A-18N/A
3/31/20171-22N/A-16N/A
12/31/20161-22N/A-13N/A
9/30/20161-17N/A-12N/A
6/30/20161-21N/A-11N/A
3/31/20161-18N/A-10N/A
12/31/20151-15N/A-10N/A
9/30/20151-25N/A-9N/A
6/30/20151-21N/A-6N/A
3/31/20151-30N/A-5N/A
12/31/20141-30N/A-2N/A
9/30/20141-19N/A-1N/A
6/30/20141-17N/A-2N/A
3/31/20141-3N/A0N/A
12/31/201322N/A0N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ABEO de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ABEO de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ABEO de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ABEO ( 62.7% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van ABEO ( 62.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ABEO naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven